Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2019

Shelley Wood

August 30, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

Advertisement

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Top Coronary Artery Disease News of 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

TCTMD’s Top 10 Most Popular Stories for September 2019

TCTMD’s Top 10 Most Popular Stories for August 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

TCTMD’s Top 10 Most Popular Stories for November 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content